Effect of the strength of adsorption of HIV 1 SF162dV2gp140 to aluminum-containing adjuvants on the immune response

Bethany Hansen, Padma Malyala, Manmohan Singh, Yide Sun, Indresh Srivastava, Harm HogenEsch, Stanley L. Hem

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

The importance of the strength of antigen adsorption by aluminum-containing adjuvants on immunopotentiation was studied using HIV 1 SF162dV2gp140 (gp140), a potential HIV/AIDS antigen. The strengths of adsorption by aluminum hydroxide (AH) adjuvant and aluminum phosphate adjuvant, as measured by the Langmuir adsorptive coefficient, were 1900 and 400 mL/mg, respectively. The strength of adsorption by AH was modified by pretreatment of AH with two different concentrations of potassium dihydrogen phosphate to produce phosphate-treated aluminum hydroxide adjuvants having adsorptive coefficients of 1200 and 800 mL/mg. The four adjuvants were used to prepare vaccines containing either 1 or 10 μg of gp140 per dose. Antibody studies in mice revealed that the presence of an adjuvant increased the immune response in comparison with a solution of gp140 when the dose was 1 μg. Furthermore, the immune response was inversely related to the adsorptive coefficient. In contrast, no significant difference in immunopotentiation was observed between treatments in the presence or absence of an adjuvant when the dose of gp140 was 10 μg. Analysis of the binding of gp140 to CD4 and anti-gp140 monoclonal antibodies by surface plasmon resonance suggests that tight binding induced structural changes in the antigen.

Original languageEnglish (US)
Pages (from-to)3245-3250
Number of pages6
JournalJournal of Pharmaceutical Sciences
Volume100
Issue number8
DOIs
StatePublished - Aug 2011
Externally publishedYes

Fingerprint

Aluminum Hydroxide
Aluminum
Adsorption
HIV-1
HIV Antigens
Antigens
Surface Plasmon Resonance
Vaccines
Phosphates
Monoclonal Antibodies
GP 140
Antibodies

Keywords

  • Excipients
  • Protein formulation
  • Proteins
  • Vaccine adjuvants
  • Vaccines

ASJC Scopus subject areas

  • Medicine(all)
  • Pharmaceutical Science

Cite this

Effect of the strength of adsorption of HIV 1 SF162dV2gp140 to aluminum-containing adjuvants on the immune response. / Hansen, Bethany; Malyala, Padma; Singh, Manmohan; Sun, Yide; Srivastava, Indresh; HogenEsch, Harm; Hem, Stanley L.

In: Journal of Pharmaceutical Sciences, Vol. 100, No. 8, 08.2011, p. 3245-3250.

Research output: Contribution to journalArticle

Hansen, Bethany ; Malyala, Padma ; Singh, Manmohan ; Sun, Yide ; Srivastava, Indresh ; HogenEsch, Harm ; Hem, Stanley L. / Effect of the strength of adsorption of HIV 1 SF162dV2gp140 to aluminum-containing adjuvants on the immune response. In: Journal of Pharmaceutical Sciences. 2011 ; Vol. 100, No. 8. pp. 3245-3250.
@article{a3a94fea927749a393dc36321905af44,
title = "Effect of the strength of adsorption of HIV 1 SF162dV2gp140 to aluminum-containing adjuvants on the immune response",
abstract = "The importance of the strength of antigen adsorption by aluminum-containing adjuvants on immunopotentiation was studied using HIV 1 SF162dV2gp140 (gp140), a potential HIV/AIDS antigen. The strengths of adsorption by aluminum hydroxide (AH) adjuvant and aluminum phosphate adjuvant, as measured by the Langmuir adsorptive coefficient, were 1900 and 400 mL/mg, respectively. The strength of adsorption by AH was modified by pretreatment of AH with two different concentrations of potassium dihydrogen phosphate to produce phosphate-treated aluminum hydroxide adjuvants having adsorptive coefficients of 1200 and 800 mL/mg. The four adjuvants were used to prepare vaccines containing either 1 or 10 μg of gp140 per dose. Antibody studies in mice revealed that the presence of an adjuvant increased the immune response in comparison with a solution of gp140 when the dose was 1 μg. Furthermore, the immune response was inversely related to the adsorptive coefficient. In contrast, no significant difference in immunopotentiation was observed between treatments in the presence or absence of an adjuvant when the dose of gp140 was 10 μg. Analysis of the binding of gp140 to CD4 and anti-gp140 monoclonal antibodies by surface plasmon resonance suggests that tight binding induced structural changes in the antigen.",
keywords = "Excipients, Protein formulation, Proteins, Vaccine adjuvants, Vaccines",
author = "Bethany Hansen and Padma Malyala and Manmohan Singh and Yide Sun and Indresh Srivastava and Harm HogenEsch and Hem, {Stanley L.}",
year = "2011",
month = "8",
doi = "10.1002/jps.22555",
language = "English (US)",
volume = "100",
pages = "3245--3250",
journal = "Journal of Pharmaceutical Sciences",
issn = "0022-3549",
publisher = "John Wiley and Sons Inc.",
number = "8",

}

TY - JOUR

T1 - Effect of the strength of adsorption of HIV 1 SF162dV2gp140 to aluminum-containing adjuvants on the immune response

AU - Hansen, Bethany

AU - Malyala, Padma

AU - Singh, Manmohan

AU - Sun, Yide

AU - Srivastava, Indresh

AU - HogenEsch, Harm

AU - Hem, Stanley L.

PY - 2011/8

Y1 - 2011/8

N2 - The importance of the strength of antigen adsorption by aluminum-containing adjuvants on immunopotentiation was studied using HIV 1 SF162dV2gp140 (gp140), a potential HIV/AIDS antigen. The strengths of adsorption by aluminum hydroxide (AH) adjuvant and aluminum phosphate adjuvant, as measured by the Langmuir adsorptive coefficient, were 1900 and 400 mL/mg, respectively. The strength of adsorption by AH was modified by pretreatment of AH with two different concentrations of potassium dihydrogen phosphate to produce phosphate-treated aluminum hydroxide adjuvants having adsorptive coefficients of 1200 and 800 mL/mg. The four adjuvants were used to prepare vaccines containing either 1 or 10 μg of gp140 per dose. Antibody studies in mice revealed that the presence of an adjuvant increased the immune response in comparison with a solution of gp140 when the dose was 1 μg. Furthermore, the immune response was inversely related to the adsorptive coefficient. In contrast, no significant difference in immunopotentiation was observed between treatments in the presence or absence of an adjuvant when the dose of gp140 was 10 μg. Analysis of the binding of gp140 to CD4 and anti-gp140 monoclonal antibodies by surface plasmon resonance suggests that tight binding induced structural changes in the antigen.

AB - The importance of the strength of antigen adsorption by aluminum-containing adjuvants on immunopotentiation was studied using HIV 1 SF162dV2gp140 (gp140), a potential HIV/AIDS antigen. The strengths of adsorption by aluminum hydroxide (AH) adjuvant and aluminum phosphate adjuvant, as measured by the Langmuir adsorptive coefficient, were 1900 and 400 mL/mg, respectively. The strength of adsorption by AH was modified by pretreatment of AH with two different concentrations of potassium dihydrogen phosphate to produce phosphate-treated aluminum hydroxide adjuvants having adsorptive coefficients of 1200 and 800 mL/mg. The four adjuvants were used to prepare vaccines containing either 1 or 10 μg of gp140 per dose. Antibody studies in mice revealed that the presence of an adjuvant increased the immune response in comparison with a solution of gp140 when the dose was 1 μg. Furthermore, the immune response was inversely related to the adsorptive coefficient. In contrast, no significant difference in immunopotentiation was observed between treatments in the presence or absence of an adjuvant when the dose of gp140 was 10 μg. Analysis of the binding of gp140 to CD4 and anti-gp140 monoclonal antibodies by surface plasmon resonance suggests that tight binding induced structural changes in the antigen.

KW - Excipients

KW - Protein formulation

KW - Proteins

KW - Vaccine adjuvants

KW - Vaccines

UR - http://www.scopus.com/inward/record.url?scp=79958819334&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79958819334&partnerID=8YFLogxK

U2 - 10.1002/jps.22555

DO - 10.1002/jps.22555

M3 - Article

C2 - 21425166

AN - SCOPUS:79958819334

VL - 100

SP - 3245

EP - 3250

JO - Journal of Pharmaceutical Sciences

JF - Journal of Pharmaceutical Sciences

SN - 0022-3549

IS - 8

ER -